ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

FTI Consulting Announces the Election of Elsy Boglioli as an Independent Director

WASHINGTON, April 10, 2023 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced that its Board of Directors (the “Board”) elected Elsy Boglioli as a director of the Company effective on April 7, 2023. Ms. Boglioli joins the Board as an independent director, following the action of the Board on April 6, 2023 to increase its overall size to ten directors from nine directors effective April 7, 2023.

Ms. Boglioli, age 41, founded and has been the Chief Executive Officer of Bio-Up, a consulting firm providing advisory services to companies in the healthcare technology field, since September 2019. From December 2017 to August 2019, Ms. Boglioli served as Executive Vice President and Chief Operating Officer of Cellectis, a clinical-stage biopharmaceutical company focusing on cell therapies. From January 2006 to November 2017, Ms. Boglioli was employed by the Boston Consulting Group, where she most recently served as a Partner and Managing Director, as well as leader of its biotech-focused business in Europe and as a member of its global Strategy and Biopharma practice leadership teams. Ms. Boglioli has served as a member of the Board of Directors of GenSight Biologics S.A., a French publicly held biopharma company focusing on gene therapies, since October 2020, and serves as the Chair of the Nomination Committee. Ms. Boglioli has also served as a member of the Board of Directors of OSE Immunotherapeutics S.A., a French publicly held clinical-stage biotechnology company focused on immunotherapies, since July 2021, and is a member of its Nomination and Remuneration Committee. She is also the Chair of the Board of Directors of TreeFrog Therapeutics, a privately held biotechnology company focused on expanding access to cell therapies, and is a member of the Boards of Directors of other privately held companies in the healthcare technologies field: Inova.io, Laverock Therapeutics, Metafora Biosystems and Womed Tech.

“I am delighted to welcome Elsy to the FTI Consulting Board,” said Gerard E. Holthaus, non-executive Chairman of the Board of FTI Consulting. “With more than 15 years of professional services experience in building businesses in international markets, Elsy will be a great asset to our Board.”

Commenting on her election, Ms. Boglioli said, “FTI Consulting has experienced tremendous growth in the last several years, and I am thrilled to be joining the Company’s Board. I look forward to working with my fellow directors to guide the next chapter of growth and expansion of FTI Consulting.”

About FTI Consulting
FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 7,600 employees located in 31 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $3.03 billion in revenues during fiscal year 2022. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. For more information, visit www.fticonsulting.com.

FTI Consulting, Inc.
555 12th Street NW
Washington, D.C. 20004
+1.202.312.9100

Investor & Media Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com 


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.